Sanofi

This study aims to see if a new 21-valent pneumococcal vaccine (PCV21) is safe and helps the body build protective antibodies in children and teens with sickle cell disease. It will compare the new vaccine to an already licensed vaccine. About 100 participants aged 2 to 17 will r…

This study is testing a new vaccine designed to protect against four types of meningococcal bacteria (A, C, Y, W) that can cause serious meningitis and blood infections. It will involve about 1,602 healthy children and adolescents aged 2 to 17 in China. Researchers will compare t…

This study is testing a new version of a vaccine that protects against serious bacterial infections like pneumonia and meningitis. It will compare the safety and immune response of the new 21-strain vaccine against a currently licensed 20-strain vaccine in healthy infants. Babies…

This study is testing the safety of a new pneumococcal vaccine (PCV21) designed to protect against 21 strains of bacteria that can cause pneumonia, meningitis, and ear infections. It will compare the new vaccine to an already approved 20-strain vaccine in about 2,320 healthy infa…

This study is testing a new yellow fever vaccine (called vYF) in children aged 9 months to 5 years. Researchers want to see if it is as safe and effective at building immunity as two already-approved yellow fever vaccines. The study will also check if the new vaccine works well w…

This study aims to evaluate the long-term safety and effectiveness of an investigational drug called SAR447537 (INBRX-101) for adults with emphysema caused by Alpha-1 antitrypsin deficiency. The trial will follow 185 participants who continue receiving the treatment to monitor si…

This study is testing whether a new drug called riliprubart works as well as or better than the standard treatment (IVIg) for adults with chronic inflammatory demyelinating polyneuropathy (CIDP), a rare nerve disorder. Participants who are already stable on IVIg will be randomly …

This study is testing several new drug combinations for people with multiple myeloma that has returned or stopped responding to standard treatments. The main goal is to find safe and effective doses and see if these new combinations can shrink the cancer. Participants will be adu…

This study aims to observe how well the drug dupilumab controls eczema and improves quality of life over two years in real-world settings. It will follow 900 patients in Germany, aged 6 and older, who are already starting this treatment. Researchers will track symptoms, side effe…

This study is testing whether an investigational drug called SAR442970 can help control Crohn's disease symptoms and reduce intestinal inflammation. Adults with moderate to severe Crohn's disease who haven't responded well to standard treatments will receive either the drug or a …

This study is testing whether an investigational drug called riliprubart can help adults with a chronic nerve disorder called CIDP when standard treatments like steroids or immunoglobulins have not worked well enough. Participants will receive either riliprubart or a placebo (ina…

This study is testing an investigational drug called rilzabrutinib to see if it can help control Graves' disease, an autoimmune condition that causes an overactive thyroid. About 30 adult participants with Graves' disease, some with and some without related eye problems, will tak…

This study will follow 350 adults with uncontrolled COPD for two years to see how well the drug dupilumab works in real-world settings. Researchers will track if the drug improves patients' quality of life, reduces breathing flare-ups, and is safe for long-term use. The study is …

This study follows 1,000 people with early-stage Type 1 diabetes for up to 10 years after they receive teplizumab treatment in regular medical care. Researchers want to see how well the treatment delays the need for insulin and affects patients' quality of life over time. The stu…

This study is testing a drug called belumosudil in children aged 1 to 18 who have a serious condition called chronic graft-versus-host disease (cGVHD) after a bone marrow transplant. The goal is to find the right dose for younger children and see if the drug is safe and can help …

This large, late-stage study is testing an investigational drug called duvakitug for people with moderate-to-severe ulcerative colitis, a chronic inflammatory bowel disease. The goal is to see if the drug can help patients achieve clinical remission—meaning a major reduction in s…

This study is testing whether an existing injectable drug called dupilumab can help reduce mucus buildup and inflammation in the airways of people with moderate-to-severe COPD. About 218 participants, aged 40-85, will receive either dupilumab or a placebo for 24 weeks while conti…

This study is testing a single injection into the eye (called SAR402663) for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The main goal is to see if this one-time treatment is safe and if it can help control the disease, potentially redu…

This study is testing whether an investigational drug called rilzabrutinib can reduce the frequency of painful episodes (vaso-occlusive crises) in people with sickle cell disease. It will involve about 192 participants aged 10 to 65 who have experienced between 2 and 10 painful c…

This study aims to see which of two injectable diabetes medications works better at keeping blood sugar in a healthy range throughout the day. It will involve about 678 Chinese adults with type 2 diabetes whose blood sugar is not well controlled with pills alone. Participants wil…

This study is testing an investigational medicine called lunsekimig, given as an injection under the skin, for adults with a specific type of chronic obstructive pulmonary disease (COPD) that is not well-controlled. The main goal is to see if it can safely reduce the number of se…

This study aims to learn about the long-term safety and effectiveness of an investigational injectable drug called lunsekimig for adults with asthma. It is open to 900 people who have already completed one of two previous studies testing this drug. Participants will receive the i…

This study is testing whether a new injectable medication called lunsekimig can help control asthma and reduce the number of serious flare-ups in adults. It is for people with high-risk asthma who have had at least one bad attack in the past year but are not currently eligible fo…

This study is testing a new drug called SAR445877 for adults with advanced solid tumors that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug, given alone or with other cancer treatments, can help shrink tumors. The trial is …

This large, late-stage study is testing whether an intravenous drug called teplizumab can help young people (ages 1-25) who were recently diagnosed with type 1 diabetes. The goal is to see if the drug can help the body preserve its own ability to make some insulin, potentially re…

This study aims to learn how well the medication dupilumab works for people with eosinophilic esophagitis (EoE) in everyday life over two years. It will follow 150 patients in Germany who are already starting this treatment to see how it affects their symptoms, safety, and qualit…

This study aims to understand how well the drug dupilumab works for people with chronic spontaneous urticaria (CSU), also known as chronic hives, in everyday life. It will follow 400 patients in the U.S. for two years, collecting information from their medical records and their o…

This study is testing an oral medication called belumosudil to see if it can slow down chronic lung rejection in adults who had a double lung transplant at least one year ago. Participants will take either the study drug or a placebo pill for up to a year, in addition to their st…

This is the first human study of an experimental antibody drug called SAR446523 for people with multiple myeloma that has returned or stopped responding to other treatments. The trial aims to find the safest and most effective dose by testing different amounts in about 87 partici…

This study is testing three new drugs (frexalimab, brivekimig, and rilzabrutinib) to see if they can help control two rare kidney diseases, FSGS and MCD. It will involve about 84 people aged 16-75 and will compare the drugs against a placebo over 24 weeks of treatment. The main g…

This study follows adults with chronic sinusitis and nasal polyps who previously tried lunsekimig in an earlier trial. Participants will receive lunsekimig for 52 weeks to check long-term safety and see if it continues to help control symptoms like congestion and smell loss. The …

This study is testing a new way to give a combination of three drugs to adults whose multiple myeloma has returned or stopped responding to previous treatments. The main goal is to see how well the treatment works to shrink the cancer. Researchers are also looking at side effects…

This study is observing people with moderate to severe hemophilia A in Taiwan who are starting a long-acting preventative clotting factor treatment called efanesoctocog alfa. Researchers will follow up to 100 participants for five years to see how well the treatment protects thei…

This study is testing an investigational injectable medication called itepekimab for adults whose chronic sinusitis with nasal polyps is not well-controlled by standard nasal steroid sprays. Over 52 weeks, researchers will compare two dosing schedules of itepekimab against a plac…

This study is testing if a medication called dupilumab can help control severe asthma in very young children. It will involve about 90 kids, aged 2 to under 6, whose asthma is not well-managed with standard inhalers. For one year, children will receive either dupilumab or a place…

This study is testing an investigational injection called lunsekimig to see if it can help adults with a specific type of uncontrolled COPD. It aims to reduce the frequency of serious symptom flare-ups (exacerbations) and improve lung function over 48 weeks. Participants will rec…

This study is testing a drug called fitusiran to see if it can safely and effectively prevent bleeding episodes in young boys with severe hemophilia A or B. About 85 boys aged 1 to under 12 will receive the drug for up to 3 years. The main goal is to see if fitusiran reduces the …

This study is testing an investigational drug called SAR442970 to see if it can help control ulcerative colitis. It will involve about 99 adults with moderate to severe disease who haven't responded well to other treatments. The main goal is to see if the drug leads to clinical r…

This study is testing an investigational drug called SAR444336 to see if it can help adults with microscopic colitis stay in remission without needing to keep taking steroid medication. Participants must already be in remission while taking budesonide. The main goal is to see if …

This study aims to find out if the drug dupilumab can prevent or slow the long-term decline in lung function for adults with uncontrolled moderate-to-severe asthma. Over 1,300 participants will receive either dupilumab or a placebo (inactive substance) alongside their standard as…

This large, late-stage study is testing whether an investigational drug called duvakitug can help people with moderate to severe Crohn's disease stay in remission and reduce intestinal inflammation over the long term. About 671 participants who responded to the drug in a prior st…

This study is testing a new injectable medicine called itepekimab for adults whose chronic sinusitis and nasal polyps are not well-controlled by standard nasal sprays. Over 200 participants will receive either the new medicine or a placebo for one year, in addition to their usual…

This study is checking if it's safe for people with severe hemophilia A to switch from their current preventive treatment (emicizumab) to a newer one (fitusiran). It will involve about 20 male participants aged 12 and older who are already on emicizumab. Researchers will closely …

This study is testing an oral medication called rilzabrutinib for adults with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets, increasing bleeding risk. It's for people whose first treatment didn't work well or stopped working. The main goal i…

This early-stage study is testing a new drug called SAR448501 in adults with moderate-to-severe lupus or rheumatoid arthritis who haven't gotten enough relief from their current treatments. The main goal is to find safe dose levels and see how the drug behaves in the body. About …

This study aims to find the right dose of an injected medication called sarilumab for children and teenagers (ages 1-17) with a severe form of juvenile arthritis. It will test how the drug moves through the body, its safety, and if it helps control the disease. The study includes…

This study aims to understand how the drug dupilumab behaves in the body and how safe it is for children and teenagers with a severe, itchy skin condition called prurigo nodularis. About 18 participants, aged 6 months to under 18 years, will receive the drug for 24 weeks and be f…

This study aims to understand the long-term safety and effectiveness of an investigational drug called amlitelimab for people with moderate to severe eczema (atopic dermatitis). About 900 participants aged 12 and older will receive the drug as a regular injection for up to 5 year…

This study is testing a new drug called SAR441566 to see if it can help control moderate-to-severe ulcerative colitis and put the disease into remission. About 204 adults who haven't gotten enough relief from standard or advanced treatments will receive either the drug or a place…

This study is testing an investigational drug called brivekimig for people with moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin condition. It aims to see if different doses of the drug can safely reduce painful skin lumps and tunnels and improve qual…

This study is testing whether an investigational drug called frexalimab can slow the worsening of disability in adults with a progressive form of multiple sclerosis (MS) who no longer have relapses. About 900 participants will receive either frexalimab or a placebo for up to 3 ye…

This large, late-stage study is testing whether an investigational drug called duvakitug can help people with moderate-to-severe ulcerative colitis stay in remission. About 671 participants who responded to initial treatment will receive either duvakitug or a placebo for 40 weeks…

This large, late-stage study is testing an investigational drug called duvakitug for people with moderate-to-severe Crohn's disease who haven't responded well to other treatments. The main goal is to see if the drug can reduce symptoms and heal intestinal inflammation over 12 wee…

This study is testing a new drug called SAR441566 to see if it can help control Crohn's disease in adults. Researchers will compare different doses of the drug against a placebo to find the most effective and safe amount. The main goal is to see if the drug reduces inflammation i…

This study is testing whether an oral medication called rilzabrutinib can better control IgG4-related disease compared to a placebo. Over 52 weeks, researchers will measure if the drug prevents painful disease flares and reduces the need for steroid medications in 124 adult parti…

This study is testing if a new drug called frexalimab works as well and is as safe when given as a monthly shot under the skin (subcutaneous) compared to the standard monthly IV infusion. It's for adults with relapsing or certain progressive forms of multiple sclerosis (MS). The …

This study is testing whether an experimental drug called SAR441344 can safely reduce disease activity in adults with active systemic lupus erythematosus (SLE). About 116 participants will receive either the drug or a placebo for 24 weeks, in addition to their standard lupus care…

This large Phase 3 trial is testing whether a new drug called frexalimab is better at controlling relapsing multiple sclerosis than the standard daily pill, teriflunomide. It will enroll 1,600 adults with relapsing MS to see which drug more effectively reduces flare-ups and slows…

This study is testing whether an experimental drug called frexalimab can help preserve the body's remaining ability to produce insulin in people recently diagnosed with type 1 diabetes. The trial will involve 192 adults and adolescents who started insulin treatment within the las…

This study is testing an investigational injection called amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that hasn't improved enough with other advanced treatments like biologics or JAK inhibitor pills. About 390 participants will rece…

This study aims to monitor the long-term safety of TZIELD, a drug already approved to delay the onset of insulin-dependent type 1 diabetes in people at high risk. It will follow 200 patients in the US who either receive TZIELD or are not treated with it, tracking their health ove…

This study is testing a single injection into the eye to see if it is safe and can slow the progression of geographic atrophy, a severe form of age-related macular degeneration that causes permanent vision loss. It will involve about 104 participants aged 60 and older who have th…

This study aims to monitor the long-term safety and how the body's immune system responds to olipudase alfa, an enzyme replacement therapy, in children under 2 years old with acid sphingomyelinase deficiency (ASMD), a rare and serious genetic disorder. It will follow up to 10 chi…

This study is testing whether an oral medication called rilzabrutinib can safely and effectively control a rare autoimmune blood disorder called warm autoimmune hemolytic anemia (wAIHA). It will involve about 90 adults whose disease hasn't responded well to standard steroid treat…

This study is testing a new drug called SAR445399 to see if it can reduce painful skin lumps and improve quality of life for adults with moderate to severe hidradenitis suppurativa (HS). Researchers will compare two different doses of the drug against a placebo (inactive substanc…

This study is testing if a 14-day intravenous treatment called teplizumab can safely delay the progression to full-blown type 1 diabetes in Japanese children and adults aged 8 to 34. Participants are in an early stage of the disease, where they have signs of it but no major sympt…

This study is testing whether a weekly medication called efanesoctocog alfa can reduce joint swelling (synovial hypertrophy) in people with hemophilia A. About 35 participants aged 12 and older with existing joint swelling will receive the treatment for 12 months. Researchers wil…

This early-stage study is testing a new drug called SAR448501/DR-0201 in adults whose B-cell non-Hodgkin lymphoma has returned or hasn't responded to at least two prior standard treatments. The main goals are to find a safe dose and see if the drug shows any signs of fighting the…

This study is testing a new, one-time gene therapy called SAR446268 for people aged 10 to 50 with myotonic dystrophy type 1 (DM1). The main goals are to see if the treatment is safe and if it can reduce the harmful genetic material that causes the disease, potentially improving m…

This study is monitoring the safety of Beyfortus, a drug given to prevent severe RSV infections in infants and young children. It will follow 3,000 Korean children under 2 years old for 6 months after they receive the injection in real-world medical settings. The main goal is to …

This study is checking the safety and real-world effectiveness of a single shot called nirsevimab, which is designed to protect against severe Respiratory Syncytial Virus (RSV). It will enroll about 110 babies and young children up to 24 months old who are at risk during RSV seas…

This study is checking if a medicine called dupilumab, already used for moderate-to-severe eczema, can also help improve anxiety and depression in people with this skin condition. It will observe about 184 patients from Gulf countries who are starting this treatment for 6 months.…

This study is testing if an injectable drug called dupilumab can safely reduce severe, long-term itching that has no known cause. It will involve about 284 adults who have had this debilitating itch for at least six months. Participants will receive either the drug or a placebo f…

This study aims to observe how COPD patients fare while taking the medication dupilumab in real-world medical settings. Researchers will follow about 500 participants in France for three years to collect information about their health, symptoms, and any side effects. The study do…

This study aims to find children and teenagers who are at risk for type 1 diabetes before they show any symptoms. Researchers will screen 3500 kids who have a close family member with the condition, looking for specific markers in their blood. The goal is to better understand who…

This study aims to understand how the drug teplizumab affects the daily lives and health of people with early-stage type 1 diabetes. It will follow 550 people in the U.S. for five years, comparing those who received the drug to those who did not. The main goal is to measure chang…

This study aims to check if electronic health records accurately identify chlamydia infections. Researchers will analyze existing health data from over 500,000 people to see how well diagnosis codes match up with lab test results. The goal is to improve data quality for future re…

This is an early safety study to see if a single dose of an investigational drug called balinatunfib affects the electrical timing of the heart in healthy people. It will involve 44 healthy adult volunteers who will receive the drug, a placebo, and a comparison drug in a specific…

This study aims to understand how doctors in France manage adults with moderate-to-severe atopic dermatitis (eczema) who are eligible for or already receiving systemic (whole-body) medications. It will observe 600 patients in their regular care settings for one year, tracking whi…

This study aims to collect safety information on pregnant and breastfeeding women with Pompe disease who are taking the medication Nexviazyme (avalglucosidase alfa). Researchers will follow the women and their babies for up to 10 years to check for any pregnancy complications or …

This study aims to understand how people with moderate-to-severe eczema (atopic dermatitis) respond to prescription treatments in everyday life, not in a controlled clinic. It will follow 1,000 patients aged 12 and older for five years across 10 countries, tracking which treatmen…